Four Months of Rifampin or Nine Months of Isoniazid for Latent Tuberculosis in Adults

Dick Menzies(McGill University Health Centre), Andrea Benedetti(Montreal Heart Institute), M. Gninafon(McGill University Health Centre), Valéria C. Rolla(Unknown), Alioune Camara(Donka Hospital), Chantal Valiquette(McGill University Health Centre), Afrânio Lineu Kritski(Universidade Federal do Rio de Janeiro), Richard Long, Guy B. Marks(UNSW Sydney), Isaac Boakye(Komfo Anokye Teaching Hospital), Peizhi Li(Jiangnan University), Philip C. Hill(MRC Unit the Gambia), Mênonli Adjobimey(McGill University Health Centre), Karen Hornby(McGill University Health Centre), Joseph Obeng Baah(Komfo Anokye Teaching Hospital), Hamdan Al‐Jahdali(King Saud University), Boubacar Bah(Laboratoire National de Santé), Anete Trajman(Universidade Federal do Rio de Janeiro), Marie-Josée Dion(McGill University Health Centre), Raspati Cundarani Koesoemadinata(Padjadjaran University), Rovina Ruslami(McGill University Health Centre), Kevin Elwood(University of British Columbia), Lika Apriani(Padjadjaran University), Hee Jin Kim(Korea National Tuberculosis Association), Victoria J. Cook(University of British Columbia), Oumou Bah Sow(McGill University Health Centre), Vernon Hoeppner(McGill University Health Centre), Hazel Goldberg(The University of Sydney), Kevin Schwartzman(McGill University Health Centre)
New England Journal of Medicine
August 1, 2018
Cited by 392


Related Papers